News

Using a combination of luminescent and fluorescent sdAbs, this recent preprint describes the detection of endogenous CXCR4 clusters by BRET. This receptor clustering is increased upon enhanced expression in cancer cells and has been linked to cancer progression.This work has been a collaboration of researchers from Martine Smit’s group at the VU, the AUMC, and QVQ and is now online:https://www.biorxiv.org/content/10.1101/2024.12.06.627249v1 QVQ offers CXCR4-targeting sdAbs as well as various modifications via fusions and conjugations.

18 December 2024 Stephanie did her PhD at QVQ as part of the Marie-Curie ITN ONCORNET2.0 in close collaboration with the group of Martine Smit at the VU. In her PhD thesis “Nanobody formats and conjugates detecting, modulating, and targeting CXCR4”, she described the functionalization of sdAbs for various applications. These modified sdAbs were used to investigate the role of the chemokine receptor CXCR4 in cancer. Last week, 4 years of work were concluded with a great defense, that the whole QVQ team was happy to attend. What a great way to end the year – congratulations!

28 November 2024 Built with 15+ years of sdAb experience, QSyLi combines the diversity of an entire VHH germline with cutting-edge nature-inspired diversification. Designed to accelerate discovery, QSyLi eliminates immunization while enabling exploration of non-immunogenic and toxic targets. Discover how QSyLi is transforming antibody discovery with faster, animal-free workflows, designed for innovation and sustainability in biotechnology.

12 November 2024 On Nov 22nd, our scientist Stephanie Anbuhl will present in Session 4, entitled ‘New modes of drug activity’ on the NVF Autumn Meeting in Oss. The meeting is organized by NVF, Nederlandse Vereniging voor Farmacologie – Dutch Pharmacological Society. Stephie will talk about the potential of single-domain antibodies as modalities in pharmacology and drug development. Interested? Let’s get in touch and chat!

10 November 2024 QVQ’s CEO Dr. Edward Dolk will be joining the Kadans Innovation Summit on the 13th and 14th of November in London to meet leading researchers, entrepreneurs, and innovators from the Europe-wide Kadans science clusters.

08 November 2024 Our recent application note highlights the advantages of fluorescent single-domain antibodies (sdAbs) in fluorescence-based technologies and advanced imaging. Due to their small size, labeled sdAbs have a small linkage error leading to robust signals and improved resolution. They are also cleared quickly from the bloodstream and have enhanced tissue penetration leading to good signal-to-noise ratios. Find out more: https://qvquality.com/functionalization/ QVQ offers sdAbs conjugated to a variety of labels, including fluorescent dyes. Until the end of November, we have a 20% discount on all labeled sdAbs.

01 November 2024 Dr. Matti Pronker will be attending the 16th PEGS Europe Protein & Antibody Engineering Summit in Barcelona from the 5th to the 7th of November.  Matti will present his poster on the high resolution structure of the FLAG peptide in complex with the M2 anti-FLAG antibody. Besides that he will be available for all your single domain antibody engineering questions.

01 November 2024 Next week, our CSO Dr. Raimond Heukers will be present at the BIO-Europe, Europe’s premier partnering event. (November 4-5, Stockholm, Sweden). You can schedule a meeting with Raimond to discuss QVQ’s single-domain antibody services.

10 October 2024 Being a CRO, service is at the core of everything we do. From this, properly processed and analyzed data-packages are important deliverables. QVQ has partnered with DataChaperone to take data analysis and reporting workflows to the next level. For example, using the DataChaperone platform, we are now able to automatically analyze ELISA datasets and generate project update presentations and reports within minutes. The DataChaperone platform is easy to use and has the flexibility to handle diverse experiment designs. Partnering with Lars Eric Fielmich and Bas Cloin from DataChaparone creates the possibility to develop similar automated data analysis workflows for all our assay, which will boost our team’s productivity and ensure faster delivery of higher-quality and uniform result … Read more

24 September 2024 Together with fantastic collaborators at the Amsterdam University Medical Center, in particular Jeffrey Umotoy and Steven de Taeye, we have generated a set of new single-domain antibodies against the challenging tetraspannin (4TM domains) CD9 described in this recent publication. The researchers at the AUMC showed that these molecules prevented HIV-1 replication and syncytia formation. The molecules are available at QVQ.

03 July 2024 On Friday July 5th 2024, our CSO Raimond Heukers, will be at the ULLA summerschool in Leiden, to take an international group of pharmaceutical science researchers (MSc, PhD and postdocs) into the wonderful world of single domain antibodies (sdAbs). Raimond’s lecture will cover tips and tricks for the successful development, characterization and utilization of single domain antibodies against GPCRs.

24 June 2024 Our single domain antibodies (sdAbs) Q101c/Q102c detect and inhibit complement factor C5. The two single domain antibodies recently published  are available as products Q101c and Q102c. Both sdAbs recognize C5 and its R885H variant and inhibit C5 cleavage, as described in this JBC paper by Eva Struijf et al. sdAbs are availabe as unlabeled reagents or directionally labeled for immediate detection.